Neoadjuvant Chemotherapy Plus Tislelizumab Followed by Concurrent Chemoradiotherapy and Maintenance Therapy With Tislelizumab in Patients With Stage IVA Nasopharyngeal Carcinoma: A Single-arm, Phase II Trial
To estimate the efficacy and safety of tislelizumab for stage IVA locally advanced nasopharyngeal carcinoma combined with induction chemotherapy and concurrent chemoradiotherapy, followed by maintenance therapy
• The subjects are not limited by gender, age from 18 to 70 years old;
• Histopathologically confirmed non-keratinizing squamous cell carcinoma of the nasopharynx;
• Locally advanced nasopharyngeal squamous cell carcinoma diagnosed as T4 or N3 stage according to AJCC 8th edition staging;
• ECOG score 0-1;
• without distant metastasis;
• This treatment must be the first course of treatment, and has not received any anti-tumor treatment such as radiotherapy and chemotherapy, immune or biological therapy in the past.
• The expected survival is expected to be no less than 6 months.
• No contraindications to chemotherapy, immunotherapy and radiotherapy;